Pharmaceuticals in Sweden

Date: April 30, 2014
Pages: 37
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Brief Review
Delivery: E-mail Delivery (PDF)
ID: PE3396AC3FEEN
Leaflet:

Download PDF Leaflet

Pharmaceuticals in Sweden
Pharmaceuticals in Sweden industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2009-13, and forecast to 2018). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Sweden pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights
  • The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2013 annual average exchange rates.
  • The Swedish pharmaceuticals market had total revenues of $4.5bn in 2013, stagnating over the period with a compound annual rate of change (CARC) of less than -0.1% between 2009 and 2013.
  • Downward pressure on pharmaceutical prices has negatively impacted the Swedish market.
  • The performance of the market is forecast to accelerate, with an anticipated CAGR of 2.6% for the five-year period 2013 - 2018, which is expected to drive the market to a value of $5.2bn by the end of 2018.
Features

Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Sweden

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Sweden

Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Sweden pharmaceuticals market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Sweden economy

Key Questions Answered
  • What was the size of the Sweden pharmaceuticals market by value in 2013?
  • What will be the size of the Sweden pharmaceuticals market in 2018?
  • What factors are affecting the strength of competition in the Sweden pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitiors in Sweden's pharmaceuticals market?
Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
AstraZeneca PLC
Johnson & Johnson
Novartis AG
Pfizer Inc.
Macroeconomic Indicators
Country Data
Appendix
Methodology
Industry associations
Related MarketLine research

LIST OF TABLES

Table 1: Sweden pharmaceuticals market value: $ billion, 2009–13
Table 2: Sweden pharmaceuticals market geography segmentation: $ billion, 2013
Table 3: Sweden pharmaceuticals market share: % share, by value, 2013
Table 4: Sweden pharmaceuticals market value forecast: $ billion, 2013–18
Table 5: AstraZeneca PLC: key facts
Table 6: AstraZeneca PLC: key financials ($)
Table 7: AstraZeneca PLC: key financial ratios
Table 8: Johnson & Johnson: key facts
Table 9: Johnson & Johnson: key financials ($)
Table 10: Johnson & Johnson: key financial ratios
Table 11: Novartis AG: key facts
Table 12: Novartis AG: key financials ($)
Table 13: Novartis AG: key financial ratios
Table 14: Pfizer Inc.: key facts
Table 15: Pfizer Inc.: key financials ($)
Table 16: Pfizer Inc.: key financial ratios
Table 17: Sweden size of population (million), 2009–13
Table 18: Sweden gdp (constant 2000 prices, $ billion), 2009–13
Table 19: Sweden gdp (current prices, $ billion), 2009–13
Table 20: Sweden inflation, 2009–13
Table 21: Sweden consumer price index (absolute), 2009–13
Table 22: Sweden exchange rate, 2009–13

LIST OF FIGURES

Figure 1: Sweden pharmaceuticals market value: $ billion, 2009–13
Figure 2: Sweden pharmaceuticals market geography segmentation: % share, by value, 2013
Figure 3: Sweden pharmaceuticals market share: % share, by value, 2013
Figure 4: Sweden pharmaceuticals market value forecast: $ billion, 2013–18
Figure 5: Forces driving competition in the pharmaceuticals market in Sweden, 2013
Figure 6: Drivers of buyer power in the pharmaceuticals market in Sweden, 2013
Figure 7: Drivers of supplier power in the pharmaceuticals market in Sweden, 2013
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Sweden, 2013
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Sweden, 2013
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Sweden, 2013
Figure 11: AstraZeneca PLC: revenues & profitability
Figure 12: AstraZeneca PLC: assets & liabilities
Figure 13: Johnson & Johnson: revenues & profitability
Figure 14: Johnson & Johnson: assets & liabilities
Figure 15: Novartis AG: revenues & profitability
Figure 16: Novartis AG: assets & liabilities
Figure 17: Pfizer Inc.: revenues & profitability
Figure 18: Pfizer Inc.: assets & liabilities


Skip to top


The Pharmaceutical Market: Sweden US$ 1,295.00 Jan, 2013 · 92 pages
Pharmaceuticals Global Industry Almanac_2016 US$ 2,995.00 Oct, 2016 · 477 pages

Ask Your Question

Pharmaceuticals in Sweden
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: